Curing All Patients with Acute Promyelocytic Leukemia: Are We There Yet? Review uri icon

Overview

MeSH Major

  • Leukemia, Promyelocytic, Acute

abstract

  • The introduction of all-trans retinoic acid to anthracycline-based chemotherapy has revolutionized the prognosis of patients with acute promyelocytic leukemia (APL). The introduction of arsenic trioxide enabled the therapeutic approach of rationally targeted frontline protocols with minimal or no traditional cytotoxic chemotherapy and without compromise of previously established outstanding outcomes with anthracycline-based regimens. Although most of the current investigative efforts in APL are focused on developing potentially curative therapy without the exposure to toxicities and risks of DNA-disrupting agents, the cure rate can further be increased by implementing meticulous supportive care strategies that counter early coagulopathy-related deaths.

publication date

  • December 2011

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC4021483

Digital Object Identifier (DOI)

  • 10.1016/j.hoc.2011.10.002

PubMed ID

  • 22093584

Additional Document Info

start page

  • 1215

end page

  • 33, viii

volume

  • 25

number

  • 6